treatment

Among autoimmune diseases, Multiple Sclerosis is one of the most progressive and debilitating, affecting between 300,000 and 400,000 people in the United States alone. The cause of the disease remains elusive to researchers, making it extremely difficult to research and develop effective therapies for treating symptoms and reversing neural…

Much of the research and development focus for treating Multiple Sclerosis revolves around pharmaceuticals. However, the development and use of novel medical devices are also becoming a factor in treating the disease as well. A new study entitled “A dorsiflexion assist orthosis reduces the physiological cost…

The U.S. Supreme Court deliberated on a request from Teva Pharmaceutical Industries Ltd. to preserve the patent of its multiple sclerosis drug Copaxone from generic competitors until September 2015. Recent reports indicate that the court gave the company a mixed opinion. The hearing occurred this…

Concert Pharmaceuticals, Inc. will announce their latest results from the Phase 1 data of CTP-354, a drug developed to treat spasticity — a chronic condition associated with patients with brain disorders, including Multiple Sclerosis — at the next American Neurological Association’s Annual Meeting in Baltimore, Maryland. The Phase 1 randomized,…

Evotec AG, a German company specializing in the provision of drug discovery resources to biotech companies and learning institutions, announced that is going to begin three new research projects for the treatment of multiple sclerosis (MS), which will be supported by funds from the German Federal Ministry of Education…

Spanish-Filipino biopharmaceutical startup Ankar Pharma is working on a promising treatment for multiple sclerosis (MS). Dr. Ana Martinez, a professor and researcher at the Biological Research Center (CIB) of the Spanish National Council for Research (CSIC), explains that while there are several palliative treatments available on the market…

New Zealand-based Pharmaceutical Management Agency (PHARMAC) has approved the funding of new treatments for multiple sclerosis (MS), which are expected not only to reach more patients, but also be more effective in curtailing the disease’s progressive symptoms. The therapies currently funded are meant for the treatment of …

A new study entitled “NAD+ protects against EAE by regulating CD4+ T-cell differentiation” published in October issue of Nature Communications reports that NAD+ can be a future therapeutic drug to treat Multiple Sclerosis. Multiple sclerosis (MS) is a type of autoimmune disease where the inner…

Now more than ever, groundbreaking, new therapies for chronic diseases and infections come with high price tags. Earlier in the year, Gilead Sciences’ drug Sovaldi for Hepatitis C, as well as Vertex’s Kalydeco for Cystic Fibrosis, both raised eyebrows over their cost. Now, a new MS therapy is doing the…

The British National Institute for Health and Care Excellence (NICE) updated their guidelines on the provision of health care for multiple sclerosis (MS) patients in the United Kingdom, which number approximately 100,000 people. The institute recommends now that every patient who is suspected to suffer from the…

New Zealand and Australia-based Innate Immunotherapeutics Limited, a biotechnology company with offices in Sydney and Auckland, has designed and manufactured a unique immunomodulator microparticle pharmaceutical technology. This technology can be used to induce the human immune system designed to fight certain cancers and infections, or modulate certain immune…

Genzyme, a Sanofi company, has announced that the Canadian province of Québec’s Institut national d’excellence en santé et services sociaux (INESSS) has recommended that the company’s multiple sclerosis (MS) drug Lemtrada (alemtuzumab) 12 mg be included on the provincial drug formulary under “Médicament d’exception” as a second-line treatment for…

Recent research reveals that placenta-based cell therapy is both safe and effective for treating both Relapsing-Remitting and progressive forms of MS. A new study entitled “Human Placenta-Derived Cells (PDA-001) for the Treatment of Adults With Multiple Sclerosis: A Randomized, Placebo-Controlled, Multiple-Dose Study” and published in August…

A new study, entitled “The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis” published online in JAMA Neurology, reports the effect of Glatiramer acetate therapy on B cells in relapsing-remitting multiple sclerosis (MS) patients. This first-of-its-kind study could…

San Francisco Bay Area-based Glialogix, Inc., a biopharmaceutical company that specializes in developing novel treatments for multiple sclerosis (MS), announced yesterday that they have closed a Sponsored Research Agreement with Fast Forward, a non-profit organization that aims to accelerate MS treatment development. Glialogix will receive funding for one of their…

With multiple sclerosis (MS) prevalence rates still at concerning levels of 90 for every 100,000 Americans, researchers are continuously seeking to learn more about the disease, and are aggressively working to develop novel treatments and interventions for symptom management. This poses an ongoing challenge for healthcare professionals and academics,…

Funding for continued research and development into understanding, treating, and eventually curing Multiple Sclerosis continues to accelerate. Evotec AG, a German company that specializes in providing drug discovery resources to pharmaceutical and biotech companies, and learning institutions, has just announced the launch of its line-up of groundbreaking studies into MS — an…

MediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in progressive multiple sclerosis patients. As of September 15th, 150 of an expected 250 patients have enrolled for treatment, and the trial is on track to complete enrollment by the…

For the first time, an antisense oligonucleotide has been shown to be effective in treating relapse-remitting multiple sclerosis. A phase 2a clinical trial of Antisense Therapeutics Limited’s ATL1102, a CD49d antisense drug, showed that the treatment quickly reduced brain lesions in RRMS patients following the start of therapy.

Phase 3 clinical trial results from Biogen Idec and AbbVie presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRMIS) suggest that relapsing-remitting multiple sclerosis patients experience…

The nonprofit organization Accelerated Cure Project for Multiple Sclerosis is going to sponsor the launch of the Optimizing Treatment – Understanding Progression (OPT-UP) study in collaboration with biopharmaceutical company EMD Serono, Inc, a subsidiary of the german Merck KGaA. The study will enroll 2,500 MS…

The first round of 22 research grants have been awarded to projects in nine countries by the International Progressive MS Alliance, with the goal of removing barriers to developing treatments for progressive MS. The 22 projects were chosen from 195 research proposals submitted by researchers in 22 countries and…

Biogen Idec revealed data from its second year of the phase 3 ADVANCE clinical trial for the study of Plegridy as a treatment for patients with relapsing forms of multiple sclerosis, which demonstrated the positive effects of the subcutaneous injectable therapy beyond the first year…

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) last week in Boston, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), together with Active Biotech (NASDAQ OMX NORDIC:ACTI), presented new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS)…

Biogen Idec presented the five-year results from its ENDORSE phase 3 extension study of Tecfidera (dimethyl fumarate), which revealed that the treatment is able to provide strong and sustained efficacy to patients with relapsing-remitting multiple sclerosis (RRMS), at last week’s ACTRIMS-ECTRIMS summit. Not only did…

Acorda Therapeutics will present results of a study analyzing AMPYRA (dalfampridine) Extended Release Tablets in multiple sclerosis patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, held through September 10-13. Unlike many other studies of therapeutic agents, this study looked at prescribing patterns, patient compliance, and budget impact…

Biopharmaceutical company Receptos, Inc. announced that they will review data from the phase 2 portion of the RADIANCE trial, the company’s phase 2 / 3 study testing RPC1063 in the treatment of Relapsing Multiple Sclerosis (RMS). The data is being presented at the largest meeting dedicated to multiple sclerosis…

Transparency Life Sciences, LLC (TLS), the first clinical-stage drug development company based on open innovation in the world, recently received a $1.4 million Small Business Innovation Research (SBIR) grant intended for its phase IIa proof-of-concept study, which is assessing the utility of the ACE inhibitor lisinopril as an adjunctive treatment for patients with multiple…

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) taking place in Boston between September 10th and 13th, Genzyme, a Sanofi company, will present its multiple sclerosis (MS) pipeline with a new group of trial treatments for early development of MS.

Biogen Idec, one of the first true biotech companies specializing in products indicated for neurodegenerative diseases, hematologic conditions, and autoimmune disorders, is preparing to present over 90 poster presentations during this week’s 6th Joint ACTRIMS-ECTRIMS Meeting. The event is scheduled to take place from Wednesday, September 10th through Saturday the…